A Swiss-headquartered medtech holding carrying German production and Austrian R&D arrived in front of US hospital procurement with a CE-marked product, an MDR file calibrated for European notified-body review, and a US-facing surface that did not survive the first FDA-aware procurement reader. The engagement opened in Cross-Border Build and rolled into Group Partnership.
BRIDGE.
The Swiss holding ran a three-country operating shape. Group head office in German-speaking Switzerland, production in southern Germany, R&D in Austria. A multi-year CE pathway under EU MDR carried by an in-house regulatory affairs lead and a European notified-body relationship. Hospital-system installed base across Switzerland, Germany, Austria, and selected Benelux accounts. The principal voice on the home-market site was clinical-evidence-led and notified-body-careful.
The trigger was a US hospital pilot opening through a US distributor relationship. The hospital procurement office wrote back asking for the 510(k) submission status, the US regulatory point-of-contact, the predicate device used in the substantial-equivalence claim, the US-side clinical-evidence summary written for an FDA reader, and a USD pricing posture. The European MDR file, the clinical study pack, and the CE certificate were all in order. The US-facing layer was a translated home-market site that opened on the EU MDR story and did not name a US regulatory contact, a US predicate, or a US pricing reference.
US hospital procurement reads 510(k) status first. If the public surface does not state it, the file is sorted into the unverified pile before clinical evidence is opened.
A US-resident regulatory contact carries more weight than the depth of the European notified-body relationship, regardless of MDR class.
CE-marked Class II devices entered the US 510(k) queue with median FDA decision timelines drifting toward six to ten months in recent cycles, per FDA premarket guidance.
The engagement opened as a Cross-Border Build, three to six months, scoped against the first product family and the active hospital pilot. The work covered the US-facing commercial layer end to end: public site, regulatory-posture page, US procurement deck, US-resident contact layer, principal LinkedIn for the group CEO and the US regulatory contact, RFQ template, and a US trade-publication posture for the next two quarters.
At month four the second product family entered FDA pre-submission. The engagement rolled into Group Partnership on a monthly retainer with a twelve-month minimum, scoped against ongoing US rebuild across the portfolio plus live support on procurement and FDA-adjacent commercial conversations. Pricing for both phases was confirmed in discovery, not on the public site.
Mid-sized European medtechs entering the United States typically underestimate the procurement-readability gap between MDR-aligned materials and an FDA-aware US hospital purchasing reader. The clinical evidence is rarely the gating issue; the framing layer is.
If your product doesn't plug directly into the specific US workflow, you are asking them to change their entire workflow just to test your tool.
| Surface element | Before the engagement | After the engagement |
|---|---|---|
| Opening fold | EU MDR pathway and notified-body history | 510(k) status, predicate claim, US contact |
| Regulatory contact | Swiss group regulatory lead, EU phone | US-resident regulatory affairs contact named |
| Clinical evidence pack | MDR Article 61 narrative | FDA-readable evidence summary |
| Pricing | EUR-denominated quotes on request | USD posture, US payment-term reference |
| Installed base reference | Switzerland, Germany, Austria, Benelux | One US pilot named, EU accounts as clinical posture |
| Hospital RFP readiness | Translated EU deck | US RFP stack with predicate-first cover |
GMA does not publish a client name, a leaked number, or a city-level identifier without explicit written opt-in from the client and, where regulated submissions are involved, from the client's regulatory counsel. The case profile above is a composite drawn from corridor patterns across Swiss-headquartered medtech holdings with German production and Austrian R&D entering the US under the MDR-to-FDA bridge. Specific outcome numbers are not published. Named case studies are added as opt-in is secured.
No legal services, no tax structuring, no immigration or visa work, no banking introductions, no regulatory licensing or 510(k) submission preparation, no fiduciary services, no IP filing, no contract drafting, no M&A advisory. FDA submission was carried by the in-house regulatory affairs lead and a US FDA submission specialist. Legal and tax structuring was carried by Swiss counsel, German counsel, and US counsel in parallel.
Is this a real client? No. This is an anonymized composite profile drawn from corridor patterns across Swiss medtech holdings entering the United States. No single client is named, no leaked numbers are published, and no neighborhood-level location is used.
Why anonymized? GMA publishes case studies only after explicit client opt-in. Until that opt-in is secured, profiles are written as anonymized composites so the structural pattern is readable without exposing client identity, contract terms, or regulated submission detail.
Can you do similar work for us? Yes if the firm fits the corridor shape: a DACH medtech holding entering the US under the MDR-to-FDA bridge, with a US-facing commercial layer not yet aligned to FDA submission posture and US hospital procurement reading. Start with a discovery conversation to scope fit.
How does this engagement start? Discovery conversation, no charge, scoped against the structural file. If the file fits, GMA proposes a Cross-Border Build with optional roll into Group Partnership. Pricing is confirmed in discovery, not on the public site.
Sources and further reading. FDA 510(k) Premarket Notification · EU Medical Device Regulation 2017/745 · FDA Device Advice · Roland Berger Mittelstand · White & Case M&A Explorer · US BEA FDI by country and industry · Princeton Globalisation and Economic Outcomes · r/Entrepreneur: Are we misreading demand · FDA Medical Device Databases.